fumarylacetoacetate: metabolite of tyrosine; RN given for (E)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5280398 |
| CHEBI ID | 30907 |
| SCHEMBL ID | 187565 |
| MeSH ID | M0274458 |
| Synonym |
|---|
| 4-fumarylacetoacetate dianion |
| fumarylacetoacetone |
| (2e)-4,6-dioxooct-2-enedioic acid |
| CHEBI:30907 |
| 4-FUMARYL-ACETOACETATE , |
| fumarylacetoacetate |
| 4-fumarylacetoacetate |
| C01061 |
| 4-fumarylacetoacetic acid |
| 28613-33-4 |
| (2z)-4,6-dioxooct-2-enedioic acid |
| 4,6-dioxo-2e-octenedioic acid |
| LMFA01170066 |
| (e)-4,6-dioxooct-2-enedioic acid |
| 9032-59-1 |
| 2-octenedioic acid, 4,6-dioxo-, (e)- |
| fm3bv7k438 , |
| unii-fm3bv7k438 |
| SCHEMBL187565 |
| (e)-4,6-dioxo-2-octenedioate |
| (e)-4,6-dioxo-2-octenedioic acid |
| 4-fumarylacetoacetic acid(2-) |
| 4-fumarylacetoacetic acid dianion |
| fumarylacetoacetic acid |
| Q5508538 |
| DTXSID20901388 |
| (2e)-4,6-dioxo-2-octenedioic acid |
| 2-octenedioic acid, 4,6-dioxo- |
| 4,6-dioxo-2-octenedioic acid |
| (2z)4,6-dioxooct-2-enedioic acid |
| Class | Description |
|---|---|
| oxo dicarboxylic acid | Any dicarboxylic acid carrying one or more oxo groups. |
| beta-diketone | A diketone in which the two keto groups are separated by a single carbon atom. |
| dicarboxylic fatty acid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (45.40) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (15.38%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (84.62%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||